Retinopathy secondary to multiple myeloma treated with bevacizumab.
Retinopathy secondary to multiple myeloma treated with bevacizumab.
Arch Soc Esp Oftalmol. 2020 Jul 04;:
Authors: Salcedo Mafla E, Gutiérrez Benítez L, Asaad M
Abstract
The case is presented on an 80-year-old woman with IgA multiple myeloma (MM), who developed retinal changes similar to mild non-proliferative diabetic retinopathy, with micro-aneurysms and intraretinal fluid. The patient was treated with systemic chemotherapy for MM, and with bevacizumab intravitreal injections, with control of her ocular disorder for 22 months. Anti-angiogenic therapy can be useful in the control of retinopathy secondary to MM, as long as the systemic disease has been controlled.
PMID: 32636041 [PubMed - as supplied by publisher]
Source: Archivos de la Sociedad Espanola de Oftalmologia - Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research